Kalaris Therapeutics, Inc. (KLRS)
NASDAQ: KLRS · Real-Time Price · USD
2.690
+0.010 (0.37%)
Aug 1, 2025, 4:00 PM - Market closed
Company Description
Kalaris Therapeutics, Inc., a clinical-stage ophthalmology biotech company, engages in developing therapies for the treatment of neovascular retinal diseases.
Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024.
The company was incorporated in 2019 and is based in Palo Alto, California.
Kalaris Therapeutics, Inc.
| Country | United States |
| Founded | 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 14 |
| CEO | Andrew Oxtoby |
Contact Details
Address: 628 Middlefield Road Palo Alto, California 94301 United States | |
| Website | kalaristx.com |
Stock Details
| Ticker Symbol | KLRS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001754068 |
| CUSIP Number | 482929106 |
| ISIN Number | US4829291065 |
Key Executives
| Name | Position |
|---|---|
| Andrew Oxtoby | President, Chief Executive Officer and Director |
| Dr. Srinivas Akkaraju M.D., Ph.D. | Director and Co-Founder |
| Dr. Michael Philip Dybbs Ph.D. | Director and Co-Founder |
| Dr. Napoleone Ferrara M.D. | Independent Director and Co-Founder |
| Brett R. Hagen | Chief Accounting Officer and Principal Financial Officer |
| Dr. Matthew Feinsod M.D. | Chief Medical Officer |